DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cyclophosphamide (Cyclophosphamide) - Diarrhoea - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Diarrhoea (171)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cyclophosphamide where reactions include diarrhoea. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 171   Next >>

Possible Cyclophosphamide side effects in 65 year old female

Reported by a physician from Japan on 2012-08-24

Patient: 65 year old female, weighing 50.2 kg (110.6 pounds)

Reactions: Weight Decreased, Blood Bilirubin Increased, Cytomegalovirus Viraemia, Headache, Pyrexia, Interstitial Lung Disease, Oedema, Thrombocytopenia, Blood Sodium Decreased, Decreased Appetite, Vomiting, Stomatitis, Pneumonia, Alanine Aminotransferase Increased, Lymphopenia, Anaemia, Febrile Neutropenia, Rash, Blood Phosphorus Decreased, Blood Potassium Decreased, Diarrhoea, Alopecia, Aspartate Aminotransferase Increased, Neutropenia, Leukopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Adriamycin PFS
    Dosage: 30 mg/m2 x 1/4 week
    Start date: 2011-03-16

Adriamycin PFS
    Dosage: 40 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-09

Carboplatin
    Dosage: 250 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-24

Cyclophosphamide
    Dosage: 350 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-09

Etoposide
    Dosage: 100 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-24

Prednisolone
    Dosage: 40 mg/m2 x 1/4 week
    Administration route: Oral
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-09

Prednisolone
    Dosage: 1mg/kg x 1/2 week
    Start date: 2011-12-13
    End date: 2011-12-14

Prednisolone
    Dosage: 40 mg/m2 x 1/4 week
    Administration route: Oral
    Start date: 2011-03-16

Prednisolone
    Dosage: 2 mg/m2, 1x/day
    Administration route: Oral
    Start date: 2011-03-24

Ranimustine
    Dosage: 60 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-16

Vincristine Sulfate
    Dosage: 1 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-09

Vindesine Sulfate
    Dosage: 2.4 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-24

Other drugs received by patient: Mucosolvan; Lansoprazole; Sulfamethoxazole and Trimethoprim; Armodafinil; Zolpidem; Olopatadine HCL; Cefazolin Sodium; Ciprofloxacin HCL; Armodafinil; Zovirax; Magmitt; Alendronate Sodium



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from Italy on 2012-08-20

Patient:

Reactions: Abdominal Pain, Vomiting, Hypersensitivity, Nausea, Skin Toxicity, Mucosal Inflammation, Fatigue, Diarrhoea, Hepatotoxicity, Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Breast Cancer

Epirubicin
    Indication: Breast Cancer

Fluorouracil
    Indication: Breast Cancer

Herceptin
    Dosage: loading dose
    Indication: Breast Cancer

Herceptin
    Dosage: maintenance dose

Lapatinib
    Dosage: arm b
    Administration route: Oral
    Indication: Breast Cancer

Lapatinib
    Dosage: arm c
    Administration route: Oral

Paclitaxel
    Indication: Breast Cancer



Possible Cyclophosphamide side effects in male

Reported by a physician from India on 2012-08-17

Patient: male, weighing 65.0 kg (143.0 pounds)

Reactions: Diarrhoea, Febrile Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Blinded Gp2013
    Dosage: code not broken
    Indication: non-Hodgkin's Lymphoma
    Start date: 2012-08-06

Blinded Mabthera
    Dosage: code not broken
    Indication: non-Hodgkin's Lymphoma
    Start date: 2012-08-06

Blinded NO Treatment Received
    Dosage: code not broken
    Indication: non-Hodgkin's Lymphoma
    Start date: 2012-08-06

Cyclophosphamide
    Indication: non-Hodgkin's Lymphoma

Prednisone TAB
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Indication: non-Hodgkin's Lymphoma



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Nausea, Pain, Motor Dysfunction, Rash, Peripheral Sensory Neuropathy, Fatigue, Blood Potassium Decreased, Dyspepsia, Diarrhoea, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Waldenstrom's Macroglobulinaemia

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: maintenance
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: maintenance
    Indication: Lymphoma

Rituximab
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Waldenstrom's Macroglobulinaemia

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphocytic Lymphoma

Other drugs received by patient: Acetaminophen; Diphenhydramine Hydrochloride; Ondansetron



Possible Cyclophosphamide side effects in female

Reported by a physician from United States on 2012-08-16

Patient: female

Reactions: Abdominal Pain, Vomiting, Nausea, Palmar-Plantar Erythrodysaesthesia Syndrome, Febrile Neutropenia, Peripheral Sensory Neuropathy, Constipation, Fatigue, Diarrhoea, Neutropenia

Drug(s) suspected as cause:
Adriamycin PFS
    Dosage: cycle 3

Adriamycin PFS
    Dosage: cycle 4

Adriamycin PFS
    Dosage: cycle 2

Adriamycin PFS
    Dosage: cycle 1
    Indication: Breast Cancer

Cyclophosphamide
    Dosage: cycle 4

Cyclophosphamide
    Dosage: cycle 3
    Indication: Breast Cancer

Cyclophosphamide
    Dosage: cycle 1

Cyclophosphamide
    Dosage: cycle 2

Docetaxel
    Dosage: cycle 4

Docetaxel
    Dosage: cycle 3
    Indication: Breast Cancer

Docetaxel
    Dosage: cycle 2

Docetaxel
    Dosage: cycle 1

Doxorubicin Hydrochloride
    Dosage: cycle 3

Doxorubicin Hydrochloride
    Dosage: cycle 4
    Indication: Breast Cancer

Doxorubicin Hydrochloride
    Dosage: cycle 1

Doxorubicin Hydrochloride
    Dosage: cycle 2

NOV-002

NOV-002
    Dosage: administered approximately 3 hr apart
    Indication: Breast Cancer

NOV-002



Possible Cyclophosphamide side effects in

Reported by a physician from France on 2012-08-15

Patient:

Reactions: Diarrhoea

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1672 mg, unk
    Indication: Multiple Myeloma
    Start date: 2012-06-08

Dexamethasone
    Dosage: 20 mg, unk
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-06-08

Velcade
    Dosage: 2899 unk, unk
    Indication: Multiple Myeloma
    Start date: 2012-06-08

Other drugs received by patient: Valaciclovir; Esomeprazole; Atovaquone; Phenoxymethylpenicillin; Sodium Bicarbonate; Allopurinol



Possible Cyclophosphamide side effects in

Reported by a physician from United Kingdom on 2012-08-10

Patient:

Reactions: Diarrhoea, Anaemia, Dizziness, Pulmonary Mycosis, Lethargy

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1500 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-03
    End date: 2012-07-04

Doxorubicin HCL
    Dosage: 100 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-03
    End date: 2012-07-04

Prednisolone
    Dosage: 100 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-03
    End date: 2012-07-08

Rituximab
    Dosage: 750 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-03
    End date: 2012-07-04

Velcade
    Dosage: 2.6 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-03
    End date: 2012-07-04

Vincristine
    Dosage: 2 mg, unk
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-03
    End date: 2012-07-04

Other drugs received by patient: Prednisolone; Tramadol HCL; Chlorhexidine Gluconate; Omeprazole; Itraconazole; Acyclovir; Symbicort; Montelukast; Cetraben / 01561901 /; Fluconazole; Nitrofurantoin; Citalopram Hydrobromide; NEO-Mercazole TAB; Cotrim; Ferrous Fumarate; Ventolin; Enoxaparin Sodium; Metoclopramide



Possible Cyclophosphamide side effects in 46 year old female

Reported by a individual with unspecified qualification from United States on 2012-08-08

Patient: 46 year old female

Reactions: Dyspnoea, Pain in Extremity, Myelodysplastic Syndrome, General Physical Health Deterioration, Pyrexia, Pulmonary Haemorrhage, Zygomycosis, Diarrhoea, Skin Discolouration, Central Nervous System Infection, Small Intestinal Haemorrhage, Cough

Adverse event resulted in: death

Drug(s) suspected as cause:
Carmustine
    Indication: Diffuse Large B-Cell Lymphoma

Carmustine
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Dosage: 400 ug, intravenous, every two months
    Indication: Diffuse Large B-Cell Lymphoma

Cytarabine
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Indication: Diffuse Large B-Cell Lymphoma

Idarubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Melphalan (Melphalan) (Melphalen)
    Indication: Diffuse Large B-Cell Lymphoma

Melphalan Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab (Rituximab) (Rituximab)
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab (Rituximab) (Rituximab)
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma



Possible Cyclophosphamide side effects in 41 year old male

Reported by a physician from Canada on 2012-08-03

Patient: 41 year old male

Reactions: Ecthyma, Diarrhoea, Pseudomonas Infection, Febrile Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma Stage IV

Doxorubicin HCL
    Indication: B-Cell Lymphoma Stage IV

Prednisone
    Indication: B-Cell Lymphoma Stage IV

Rituximab
    Indication: B-Cell Lymphoma Stage IV

Vincristine
    Indication: B-Cell Lymphoma Stage IV

Other drugs received by patient: Epogen; Enoxaparin Sodium; Filgrastim



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-08-01

Patient:

Reactions: Nausea, Motor Dysfunction, Pain, Rash, Peripheral Sensory Neuropathy, Fatigue, Dyspepsia, Blood Potassium Decreased, Diarrhoea, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Cyclophosphamide
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Cyclophosphamide
    Dosage: on day 1

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Waldenstrom's Macroglobulinaemia

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphocytic Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance
    Indication: Waldenstrom's Macroglobulinaemia

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: non-Hodgkin's Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Waldenstrom's Macroglobulinaemia

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphocytic Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphoma

Other drugs received by patient: Diphenhydramine HCL; Acetaminophen; Ondansetron



Possible Cyclophosphamide side effects in 37 year old female

Reported by a physician from Japan on 2012-08-01

Patient: 37 year old female

Reactions: Autoimmune Pancreatitis, Diarrhoea, Chronic Graft Versus Host Disease in Skin, Chronic Graft Versus Host Disease, Acute Myeloid Leukaemia Recurrent

Adverse event resulted in: death

Drug(s) suspected as cause:
Anti-Thymocyte Globulin NOS
    Dosage: 15 mg/kg, daily dose, day -2 and day -1
    Indication: Bone Marrow Conditioning Regimen

Busulfex
    Dosage: 3.2 mg/kg, daily dose, -7 to day -4, intravenous
    Indication: Bone Marrow Conditioning Regimen

Cyclophosphamide
    Dosage: 60 mg/kg, daily dose, day -3
    Indication: Bone Marrow Conditioning Regimen

Other drugs received by patient: Gabexate Mesilate (Gabexate Mesilate); Gemtuzumab Ozogamicin (Gemtuzumab Ozogamicin); Prednisolone



Possible Cyclophosphamide side effects in

Reported by a physician from Netherlands on 2012-07-30

Patient:

Reactions: Diarrhoea, Pyrexia

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1000 mg, unk
    Indication: Multiple Myeloma
    Start date: 2012-05-04
    End date: 2012-05-11

Dexamethasone
    Dosage: 40 mg, unk
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-05-04
    End date: 2012-05-15

Velcade
    Dosage: 2.6 mg, unk
    Indication: Multiple Myeloma
    Start date: 2012-05-04
    End date: 2012-05-14



Possible Cyclophosphamide side effects in 46 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-27

Patient: 46 year old female

Reactions: Pancreatic Infarction, Unresponsive To Stimuli, Myelodysplastic Syndrome, Pyrexia, Pallor, Cerebral Haemorrhage, Skin Discolouration, Diarrhoea Haemorrhagic, Small Intestinal Haemorrhage, Apnoea, Thrombocytopenia, Cough, Candidiasis, Hepatosplenomegaly, Dyspnoea, Pain in Extremity, Anaemia, Pulmonary Haemorrhage, Zygomycosis, Diarrhoea, Hemisensory Neglect, Lung Infiltration, Asthenia, Hepatic Infarction

Adverse event resulted in: death

Drug(s) suspected as cause:
Carmustine
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Cytarabine
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Etoposide
    Indication: Diffuse Large B-Cell Lymphoma

Idarubicin HCL
    Dosage: 12 mg/m2, unk
    Indication: Myelodysplastic Syndrome

Oncovin
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Indication: Diffuse Large B-Cell Lymphoma

Suberoylanilide Hydroxamic Acid
    Dosage: 500 mg, tid
    Administration route: Oral
    Indication: Myelodysplastic Syndrome

Other drugs received by patient: Radiotherapy



Possible Cyclophosphamide side effects in female

Reported by a physician from Canada on 2012-07-26

Patient: female

Reactions: Nausea, Palmar-Plantar Erythrodysaesthesia Syndrome, Febrile Neutropenia, Rash, Mucosal Inflammation, Neuropathy Peripheral, Diarrhoea, Alopecia, Ejection Fraction Decreased, Adverse Event, Neutropenia, Cardiotoxicity, Asthenia, Cardiac Failure Congestive

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 21 day cycle
    Indication: Breast Cancer

Doxorubicin HCL
    Dosage: 21 day cycle
    Indication: Breast Cancer

Taxol
    Dosage: with trastuzumab given weekly for 12 weeks
    Indication: Breast Cancer

Trastuzumab
    Dosage: first dose 4mg/kg given weekly for 12 weeks
    Indication: Breast Cancer

Trastuzumab
    Dosage: first dose 4mg/kg given weekly for 12 weeks



Possible Cyclophosphamide side effects in 33 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-25

Patient: 33 year old female

Reactions: Hyperbilirubinaemia, Enterococcal Infection, Pyrexia, Chorioretinitis, Large Intestinal Ulcer, Abdominal Distension, Microsporidia Infection, Hydrocephalus, Meningitis, Papule, Retinal Haemorrhage, Pulmonary Alveolar Haemorrhage, Hepatic Enzyme Increased, Respiratory Failure, Diarrhoea, Fungal Infection, Aspartate Aminotransferase Increased, Dermal Cyst, Lung Infiltration, Macule, Inflammation

Adverse event resulted in: death

Drug(s) suspected as cause:
Alemtuzumab
    Indication: Multiple Myeloma

Alemtuzumab
    Indication: Prophylaxis

Cyclophosphamide
    Indication: Multiple Myeloma

Cyclosporine
    Indication: Prophylaxis

Cyclosporine
    Indication: Stem Cell Transplant

Cyclosporine
    Dosage: unk
    Indication: Multiple Myeloma

Fludarabine Phosphate
    Dosage: unk
    Indication: Multiple Myeloma



Possible Cyclophosphamide side effects in 17 year old female

Reported by a physician from United States on 2012-07-25

Patient: 17 year old female, weighing 47.6 kg (104.7 pounds)

Reactions: Blood Bilirubin Increased, Dysphagia, Muscular Weakness, Vocal Cord Paralysis, Cerebrovascular Accident, Caecitis, Eating Disorder, Diarrhoea, Depressed Level of Consciousness, Acute Respiratory Distress Syndrome, Sinus Tachycardia, Spinal Cord Oedema, Peripheral Motor Neuropathy, Epistaxis, Neuralgia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1000mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Cytarabine
    Dosage: 75mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Dalteparin Sodium
    Indication: Product Used FOR Unknown Indication

Mercaptopurine
    Dosage: 60mgm2 cyclic
    Administration route: Oral
    Indication: T-Cell Type Acute Leukaemia

Methotrexate
    Indication: T-Cell Type Acute Leukaemia

Nelarabine
    Dosage: 650mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2012-04-13

PEG-Asparaginase
    Indication: T-Cell Type Acute Leukaemia

Vincristine
    Dosage: 1.5mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Other drugs received by patient: Insulin Aspart; Lansoprazole; Vancomycin; Nystatin; Piperacillin and Tazobactam; Voriconazole



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from Thailand on 2012-07-23

Patient: female

Reactions: Diarrhoea, Chills, Febrile Neutropenia, Headache

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: every cycle
    Indication: Breast Cancer
    Start date: 2010-12-08
    End date: 2011-01-05

Epirubicin
    Dosage: every cycle
    Indication: Breast Cancer
    Start date: 2010-12-08
    End date: 2011-01-05

Fluorouracil
    Dosage: every cycle
    Indication: Breast Cancer
    Start date: 2010-12-08
    End date: 2011-01-05

Other drugs received by patient: Dexamethasone; Onsia



Possible Cyclophosphamide side effects in female

Reported by a physician from Canada on 2012-07-20

Patient: female

Reactions: Nausea, Palmar-Plantar Erythrodysaesthesia Syndrome, Febrile Neutropenia, Rash, Mucosal Inflammation, Neuropathy Peripheral, Diarrhoea, Alopecia, Ejection Fraction Decreased, Adverse Event, Cardiotoxicity, Neutropenia, Asthenia, Cardiac Failure Congestive

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 21 day cycle
    Indication: Breast Cancer

Doxorubicin HCL
    Dosage: 21 day cycle
    Indication: Breast Cancer

Taxol
    Dosage: with trastuzumab given weekly for 12 weeks
    Indication: Breast Cancer

Trastuzumab
    Dosage: first dose 4mg/kg given weekly for 12 weeks
    Indication: Breast Cancer

Trastuzumab
    Dosage: first dose 4mg/kg given weekly for 12 weeks



Possible Cyclophosphamide side effects in 44 year old female

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-07-20

Patient: 44 year old female, weighing 55.5 kg (122.1 pounds)

Reactions: Abdominal Pain, Intestinal Ischaemia, Colitis Ischaemic, White Blood Cell Count Decreased, Vomiting, Blood Creatine Phosphokinase Increased, Gastrointestinal Necrosis, Pyrexia, Multi-Organ Failure, Diarrhoea, GAS Gangrene, Heart Rate Increased, Bone Marrow Failure, Neutropenia, Clostridial Infection

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 7 cycles, total 4 courses
    Indication: Breast Cancer
    Start date: 2011-07-22
    End date: 2011-09-22

Epirubicin
    Dosage: 7 cycles, total 4 courses
    Indication: Breast Cancer
    Start date: 2011-07-22
    End date: 2011-09-22

Taxotere
    Dosage: 4 cycles, total 3 courses, dose taken once daily
    Indication: Breast Cancer
    Start date: 2011-10-14
    End date: 2011-11-25

Other drugs received by patient: Leucon; Lorazepam; Decadron Phosphate; Lorazepam; Kytril; Prochlorperazine; Kytril; Cepharanthin; Decadron Phosphate; Marzulene S



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-18

Patient:

Reactions: Pneumonia, Nausea, Lymphopenia, Hyperglycaemia, Anaemia, Febrile Neutropenia, Constipation, Renal Failure, Neuropathy Peripheral, Fatigue, Diarrhoea, Embolism, Neutropenia, Thrombocytopenia, Deep Vein Thrombosis

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 500 milligram/sq. meter
    Indication: Multiple Myeloma

Dexamethasone
    Dosage: 40 milligram
    Indication: Multiple Myeloma

Revlimid
    Dosage: 25 milligram
    Administration route: Oral
    Indication: Multiple Myeloma

Revlimid
    Dosage: 15 milligram
    Administration route: Oral

Velcade
    Dosage: 1.3 milligram/sq. meter
    Indication: Multiple Myeloma

Velcade
    Dosage: 1.3 milligram/sq. meter



Possible Cyclophosphamide side effects in male

Reported by a health professional (non-physician/pharmacist) from France on 2012-07-17

Patient: male

Reactions: Cardiac Murmur, Vomiting, Alanine Aminotransferase Increased, Hypotension, Atrial Fibrillation, Headache, Rash, Pyrexia, Diarrhoea, Oedema Peripheral, Vertigo, Neutropenia, Blood Creatinine Increased, Leukopenia, Muscle Spasms

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Bactrim
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Cyclophosphamide
    Dosage: 400 mg, qd, cycle 2
    Start date: 2012-06-02
    End date: 2012-06-04

Cyclophosphamide
    Dosage: 500 mg, qd, cycle 1
    Indication: Chronic Lymphocytic Leukaemia
    Start date: 2012-04-28
    End date: 2012-04-30

Dedrogyl
    Dosage: 15 mg/100ml (3 drps/d)
    Indication: Product Used FOR Unknown Indication

Difrarel
    Dosage: 100 mg, unk
    Indication: Product Used FOR Unknown Indication

Escitalopram
    Dosage: 10 mg, qd, 1 pill
    Indication: Product Used FOR Unknown Indication

Fludara
    Dosage: 80 mg, qd, cycle 2
    Start date: 2012-06-02
    End date: 2012-06-04

Fludara
    Dosage: 80 mg, unk, cycle 1
    Indication: Chronic Lymphocytic Leukaemia
    Start date: 2012-04-28
    End date: 2012-04-30

Mabthera
    Dosage: 755 mg, once, cycle 1
    Indication: Chronic Lymphocytic Leukaemia
    Start date: 2012-04-27
    End date: 2012-04-27

Mabthera
    Dosage: 1000 mg, once, cycle 2
    Start date: 2012-06-01
    End date: 2012-06-01

MAG 2
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Phosphoneuros
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Valacyclovir Hydrochloride
    Dosage: 500 mg, unk
    Indication: Product Used FOR Unknown Indication



Possible Cyclophosphamide side effects in 33 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-16

Patient: 33 year old female

Reactions: Hyperbilirubinaemia, Enterococcal Infection, Pyrexia, Chorioretinitis, Large Intestinal Ulcer, Abdominal Distension, Microsporidia Infection, Meningitis, Hydrocephalus, Papule, Retinal Haemorrhage, Pulmonary Alveolar Haemorrhage, Hepatic Enzyme Increased, Fungal Infection, Respiratory Failure, Diarrhoea, Aspartate Aminotransferase Increased, Dermal Cyst, Lung Infiltration, Macule, Inflammation

Adverse event resulted in: death

Drug(s) suspected as cause:
Alemtuzumab
    Indication: Multiple Myeloma

Alemtuzumab
    Indication: Prophylaxis

Cyclophosphamide
    Indication: Multiple Myeloma

Cyclosporine
    Indication: Prophylaxis

Cyclosporine
    Dosage: unk
    Indication: Multiple Myeloma

Cyclosporine
    Indication: Stem Cell Transplant

Fludarabine Phosphate
    Dosage: unk
    Indication: Multiple Myeloma



Possible Cyclophosphamide side effects in 17 year old female

Reported by a physician from United States on 2012-07-13

Patient: 17 year old female, weighing 47.6 kg (104.7 pounds)

Reactions: Blood Bilirubin Increased, Dysphagia, Muscular Weakness, Vocal Cord Paralysis, Cerebrovascular Accident, Caecitis, Eating Disorder, Diarrhoea, Depressed Level of Consciousness, Acute Respiratory Distress Syndrome, Spinal Cord Oedema, Peripheral Motor Neuropathy, Sinus Tachycardia, Neuralgia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1000mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Cytarabine
    Dosage: 75mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Dalteparin Sodium
    Indication: Product Used FOR Unknown Indication

Mercaptopurine
    Dosage: 60mgm2 cyclic
    Administration route: Oral
    Indication: T-Cell Type Acute Leukaemia

Methotrexate
    Indication: T-Cell Type Acute Leukaemia

Nelarabine
    Dosage: 650mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2012-04-13

PEG-Asparaginase
    Indication: T-Cell Type Acute Leukaemia

Vincristine
    Dosage: 1.5mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Other drugs received by patient: Insulin Aspart; Nystatin; Voriconazole; Vancomycin; Piperacillin and Tazobactam; Lansoprazole



Possible Cyclophosphamide side effects in

Reported by a physician from Netherlands on 2012-07-12

Patient:

Reactions: Diarrhoea, Pyrexia

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1000 mg, unk
    Indication: Multiple Myeloma
    Start date: 2012-05-04
    End date: 2012-05-11

Dexamethasone
    Dosage: 40 mg, unk
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-05-04
    End date: 2012-05-15

Velcade
    Dosage: 2.6 mg, unk
    Indication: Multiple Myeloma
    Start date: 2012-05-04
    End date: 2012-05-14



Possible Cyclophosphamide side effects in male

Reported by a physician from Germany on 2012-07-12

Patient: male

Reactions: Stomatitis, Diarrhoea, Dehydration, Pain of Skin, Palmar-Plantar Erythrodysaesthesia Syndrome, Gastrointestinal Inflammation

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1640 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-17

Doxorubicin HCL
    Dosage: 110 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-17

Neulasta
    Dosage: 6 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-20

Prednisone
    Dosage: 100 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-17

Rituximab
    Dosage: 800 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-16

Vincristine
    Dosage: 2 mg, q2wk
    Indication: B-Cell Lymphoma
    Start date: 2012-04-17

Other drugs received by patient: Bisoprolol Fumarate; Simvastatin; Amiodarone Hydrochloride; Levothyroxine Sodium; Digitoxin TAB



Possible Cyclophosphamide side effects in

Reported by a individual with unspecified qualification from United States on 2012-07-11

Patient:

Reactions: Weight Decreased, Thrombosis, Pruritus, Hypokalaemia, Fatigue, Depression, Thrombocytopenia, Alanine Aminotransferase Abnormal, Blood Antidiuretic Hormone Abnormal, Dyspnoea, Nausea, Lymphopenia, Haemoglobin Abnormal, Hyponatraemia, Febrile Neutropenia, Palmar-Plantar Erythrodysaesthesia Syndrome, Rash, Diarrhoea, Embolism, Blood Alkaline Phosphatase Abnormal, Dehydration, Neutropenia, Leukopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on days 1-14
    Administration route: Oral
    Indication: Breast Cancer Metastatic

Xeloda
    Dosage: beginning on day 8 and continuing to day 21 (total of 14 days)
    Administration route: Oral
    Indication: Breast Cancer Metastatic



Possible Cyclophosphamide side effects in 17 year old female

Reported by a physician from United States on 2012-07-09

Patient: 17 year old female, weighing 47.6 kg (104.7 pounds)

Reactions: Blood Bilirubin Increased, Dysphagia, Cerebrovascular Accident, Caecitis, Eating Disorder, Dysphonia, Diarrhoea, Acute Respiratory Distress Syndrome, Depressed Level of Consciousness, Peripheral Motor Neuropathy, Sinus Tachycardia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1000mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Cytarabine
    Dosage: 75mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Dalteparin Sodium
    Indication: Product Used FOR Unknown Indication

Mercaptopurine
    Dosage: 60mgm2 cyclic
    Administration route: Oral
    Indication: T-Cell Type Acute Leukaemia

Methotrexate
    Indication: T-Cell Type Acute Leukaemia

Nelarabine
    Dosage: 650mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2012-04-13

PEG-Asparaginase
    Indication: T-Cell Type Acute Leukaemia

Vincristine
    Dosage: 1.5mgm2 cyclic
    Indication: T-Cell Type Acute Leukaemia

Other drugs received by patient: Lansoprazole; Piperacillin and Tazobactam; Vancomycin; Voriconazole; Insulin Aspart; Nystatin



Possible Cyclophosphamide side effects in male

Reported by a physician from Germany on 2012-07-09

Patient: male

Reactions: Stomatitis, Diarrhoea, Pain of Skin, Dehydration, Gastrointestinal Inflammation, Palmar-Plantar Erythrodysaesthesia Syndrome

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-04-17

Cyclophosphamide
    Dosage: reduced dose
    Start date: 2012-06-05

Doxorubicin HCL
    Indication: B-Cell Lymphoma
    Start date: 2012-04-17

Doxorubicin Hydrochloride
    Dosage: reduced dose
    Start date: 2012-06-05

Mabthera
    Dosage: reduced dose
    Start date: 2012-06-05

Mabthera
    Indication: B-Cell Lymphoma
    Start date: 2012-04-16

Pegfilgrastim
    Indication: B-Cell Lymphoma
    Start date: 2012-04-20

Prednisone TAB
    Dosage: reduced dose
    Start date: 2012-06-05

Prednisone TAB
    Indication: B-Cell Lymphoma
    Start date: 2012-04-17

Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-04-17

Vincristine
    Dosage: reduced dose
    Start date: 2012-06-05

Other drugs received by patient: Bisoprolol Fumarate; Simvastatin; Levothyroxine Sodium; Digitoxin TAB; Amiodarone HCL



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-07-05

Patient:

Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Dyspnoea, Stomatitis, Vomiting, Gastrointestinal Toxicity, Nausea, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Diarrhoea, Respiratory Failure, Neurological Symptom, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 2,4 and 6

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 2,4 and 6

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6

Prednisone
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Lymphoma

Prednisone
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Other drugs received by patient: Filgrastim; Unknown Medication; Leucovorin Calcium



Possible Cyclophosphamide side effects in 11 year old female

Reported by a physician from Japan on 2012-07-03

Patient: 11 year old female

Reactions: Epstein-Barr Virus Infection, Hepatic Function Abnormal, Diarrhoea, Cystitis Haemorrhagic, BK Virus Infection, Lymphoproliferative Disorder

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 40 mg/kg, unk
    Indication: Bone Marrow Conditioning Regimen

Fludara
    Dosage: 120 mg/m2, unk
    Indication: Bone Marrow Conditioning Regimen

Thymoglobulin
    Dosage: 10 mg/kg, unk
    Indication: Bone Marrow Conditioning Regimen

Other drugs received by patient: Total Body Irradiation; Methotrexate; Tacrolimus



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017